- Global Pharma News & Resources

Thebaine Market Top Companies Trends, Product Innovations, Technology and Revenue Status: Coherent Market Insights

SEATTLE, April 08, 2021, (PHARMIWEB) — Thebaine is an opioid alkaloid also known as codeine methyl enol ether. Although it is a minor constituent of opium, thebaine is chemically similar to codeine and morphine, thebaine has stimulatory effects instead of depressant effects. Thebaine is white crystalline substance, which is slightly soluble in water. It is more lethal compared to morphine, hence it is a poisonous alkaloid. High doses thebaine can cause convulsions, which is similar to strychnine poisoning. Synthetic enantiomer of thebaine show analgesic effects, which is mediated through opioid receptors.

*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @

Pharmacodynamics of thebaine such as it has a stimulatory effect by acting on opioid receptors, which are present in the central nervous system. Thebaine is a main alkaloid extracted from papaver bracteatum and it can be converted industrially into a number of compounds such as oxycodone, nalbuphine, oxymorphone, naltrexone, naloxone, and buprenorphine, which has therapeutic applications. Thebaine is listed as class A drug under the Misuse of Drugs Act 1971 in the U.K. In the U.S, it is listed as Schedule II Drug as per Analog Act. In Canada, thebaine is listed as Schedule 1 Drug substance under the Controlled Drugs and Substances Act.

Thebaine Market drivers:-

Moreover, launch of new campaigns to promote drug abuse treatment is expected to be a major driver for growth of global thebaine market over the forecast period. For instance, in 2018, White House Administration launched a multi-million dollar opioid awareness campaign for young adults. This campaign aims at curbing addition of opioid among young population. This campaign also spreads awareness by sharing true life stories of drug addicts to educate teens as well as young adults. According to a survey conducted by Substance Abuse and Mental health Services administration in 2018, opioid crisis kills an average of 116 U.S. population annually. Such government organized campaigns and high number of people dying due to opioid crisis are expected to encourage people to get rid of substance abuse addiction using different treatments available to live a healthy life.

Robust pipeline of thebaine drugs is expected to drive thebaine market growth over the forecast period. For instance, in 2017, National Institute of Health and Welfare’s drug Naloxone hydrochloride 20mg/ml completed phase 2 clinical trials. Naloxone hydrochloride is used to treat opioid drug abuse. Moreover, University of British Coloumbia’s drug Naloxone completed phase 2 in 2016. Naloxone is used to treat pain related to post-operation process as well as acute pain treatment. Trevi Therapeutics’s drug Albuphine Hcl ER tablets 90 mg has completed phase 2 clinical trials in 2016. Albuphine HCl ER tablets 90 mg is used to treat Prurigo Nodularis, which is a nodular skin disease.

Increasing number of drug abuse patients is also expected to boost growth of the thebaine market. According to a survey conducted by Center for Disease Control and prevention (CDC), in 2017, more than 2 million people died due to opioid overdose.

Ban of certain thebaine drugs is a major factor that is expected to hamper thebaine market growth. For instance, in 2017, FDA advised manufacturers to remove oxymorphone from the market due to opioid crisis.

Thebaine Market Regional Analysis:-

North America is expected to hold dominant position in global thebaine market due to robust pipeline. For instance, New York state Psychiatric Institute’s drug Pioglitazone (oxycodone) has completed Phase 2 clinical trials in 2016. Pioglitazone (oxycodone) is used in the treatment of drug abuse (Opioid Abuse). Launch of new drugs is expected to fuel theabine market growth. For instance, in 2017, ANI Pharmaceuticals Inc., a specialty pharmaceutical company, launched Oxycodone Hydrochloride Oral Solution 100m/5ml. Oxycodone Hydrochloride Oral Solution is used to treat acute pain.

Europe thebaine market is expected to witness significant growth due to robust pipeline of thebaine drugs. For instance, University children’s hospital’s drug Nalbuphine completed Phase 1 clinical trials in 2017. Nalbuphine is used to treat pain related to intravenous injections especially for used in infants.

Launch of new generic drugs is expected to support Asia Pacific thebaine market growth. For instance, in 2017, Daiichi Sankyo Company Ltd., a global pharmaceutical company launched generic version of oxycodone immediate release formulation. Oxycodone immediate release formulation, which is used to treat cancer pain.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @

Thebaine Market Key Players:-

Key players operating in the global thebaine market include API Labs Inc., Alcaliber S.A., Sanofi S.A., Faran Shimi pharmaceutical Co., Mallinckrodt Pharmaceuticals, Noramco Inc., and Tasmania Alkaloids Pvt. Ltd.

Thebaine Market Taxonomy:-

By Applications:

  • Oxymorphone
  • Nalbuphine
  • Naltrexone
  • Naloxone
  • Oxycodone
  • Buprenorphine
  • Others

By Distribution Channels:

  • Hospitals/Clinics
  • Online Pharmacies
  • Retail pharmacies

By Region:

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East
  • Africa
About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 08-Apr-2021